These Biopharma Funds Made a Comeback Last Year

While some funds posted huge losses in 2022, several others managed to turn sharp losses into profitability.

Andrey Rudakov/Bloomberg

Andrey Rudakov/Bloomberg

After a disastrous first half of the year, at least three biopharma hedge funds finished 2022 in the black, while another came close to being profitable.

For most of these firms — which rarely make significant changes to their top holdings from quarter to quarter — it was simply a case of watching their favorite stocks recover after a long string of losses.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.